Apr 14,2022

DarioHealth Announces Agreement with Health Plan Colorado Access

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today a new agreement with Colorado Access, the largest public sector health plan in the state of Colorado, to provide digital chronic condition management solutions for its Medicaid population beginning with thousands of its members in the second quarter of 2022.

COLLABORATION PARTNERSHIP

#insurance

#coaching

#virtual care

View Analyst & Ambassador Comments
Go to original news
May 08,2022

Japan clears CureApp's DTx app for hypertension

Japan's Ministry of Health, Labour and Welfare has awarded the Japanese medtech startup CureApp a medical device regulatory approval for its digital therapeutic app for hypertension. CureApp's latest DTx app assists patients in maintaining lifestyle improvements as part of their treatment for hypertension. It automatically delivers personalised guidance to users, including advice on diet, exercise, and sleep, which are captured via blood pressure monitoring, as well as lifestyle habit logs and notifications about behavioural changes.

PRODUCT

#mobile app

#rpm

#virtual care

View Analyst & Ambassador Comments
Go to original news
May 19,2022

DarioHealth Announces Additional Commercial Contracts for its Digital Therapeutic Solutions

DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today two new contracts to provide digital therapeutics solutions to a national employer and a provider, both of which are expected to begin enrolling members in the third quarter of 2022.

PRODUCT

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 03,2022

DarioHealth Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association's 82nd Scientific Sessions

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today three new research studies presented at the American Diabetes Association's ("ADA") 82nd Scientific Sessions being held June 3rd to 7th, 2022 in New Orleans, Louisiana.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 16,2022

Welldoc Granted 31st Patent for First-in-Class Chronic Care Platform

Welldoc®, a digital health leader revolutionizing chronic care, today announced that the company’s 31st patent was granted on June 14, 2022, demonstrating the continued advancement of Welldoc’s first-in-class technology for comprehensive chronic condition management. Welldoc’s portfolio includes patents from the U.S. Patent and Trademark Office and IP Australia.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 21,2022

DarioHealth Demonstrates Continued Growth in Multi-Chronic Contracts with Latest Addition of a National Employer for the Full Solution Suite

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced a new contract to deliver its full suite of integrated chronic condition management solutions to a national employer. The new account is expected to launch in the third quarter of 2022.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 19,2022

Japanese DTx app maker CureApp to receive $51M investment from Carlyle

Japanese medical technology firm CureApp is getting 7 billion yen ($51.4 million) in investment from global investment firm Carlyle as part of their strategic partnership. Carlyle is taking a minority stake in the company, which has so far raised 13.4 billion yen ($98 million) in capital funding.

FUNDING SERIES G
View Analyst & Ambassador Comments
Go to original news
Sep 20,2022

DarioHealth Announces Two New Employer Contracts

DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today two new employer contracts, including one for the full suite of integrated solutions. The new accounts are scheduled to launch in late 2022 and early 2023.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 21,2022

New Study Published in an American Heart Association Journal Indicates that Hello Heart’s Digital Coaching App Could Contribute to Heart Health Equity

Hello Heart, the only digital therapeutic that focuses exclusively on heart health, has released a new study evaluating the program's results for various user population groups in order to demonstrate its effectiveness related to diversity, equity, and inclusion (DEI). The study, published as an abstract in the American Heart Association’s Hypertension journal, indicates that Hello Heart’s hypertension digital coaching program could contribute to health equity, showing similar improvements in heart health for a range of populations, across gender, age, race, and more.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 13,2022

Dario's Full Suite of Digital Solutions Selected by Midwestern City to Improve Employee Health

DarioHealth Corp. ("Dario" or the "Company") (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that a mid-sized Midwestern city (the "City") selected Dario to provide its full suite of digital therapeutics solutions to several thousand city employees beginning in the first quarter of 2023.

PRODUCT

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to HYPERTENSION